AMPK-Directed Therapeutics for MASLD: Mechanistic Rationale, Activator Classes, and Clinical Translation
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188358 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Reeju Amatya und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju Daero, Jinju 52828, Gyeongnam, Repub…. Hauptthemen laut MEDLINE: AMP-Activated Protein Kinases, Fatty Liver, Non-alcoholic Fatty Liver Disease, Enzyme Activators. Die Arbeit nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT, Ministry of Education, Ministry of Food and Drug Safety.
Abstract (Originalsprache)
Metabolic-associated steatotic liver disease (MASLD) affects an estimated 25–30% of the global adult population and represents a leading cause of liver-related morbidity. However, approved pharmacological therapies remain strictly limited. AMP-activated protein kinase (AMPK), a highly conserved heterotrimeric serine/threonine kinase and major regulator of cellular energy homeostasis, is chronically suppressed in the steatotic liver through hyperinsulinemia, ceramide signaling, oxidative stress, and epigenetic silencing of its upstream activator LKB1. This suppression removes a critical brake on de novo lipogenesis while simultaneously impairing fatty acid β-oxidation, mitochondrial quality control, anti-inflammatory signaling, and hepatic stellate cell quiescence. Thus, AMPK restoration may serve as an effective strategy capable of addressing multiple pathological drivers of MASLD. This review examines the molecular architecture of the AMPK heterotrimer, the downstream signaling networks governing hepatic lipid metabolism, glucose homeostasis, and fibrogenesis, and a spectrum of AMPK-activating pharmacology relevant to MASLD. Furthermore, it would introduce indirect activators including metformin, berberine, resveratrol, and related phytochemicals, as well as direct allosteric activators targeting the ADaM site, such as A-769662, PF-06409577, MK-8722, Compound 991, and the clinical-stage compound O304. Translational challenges confronting this therapeutic class are critically evaluated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju Daero, Jinju 52828, Gyeongnam, Republic of Korea.
- Phytoeco, Inc., Bldg. B, Room 404, 197 Injero, Gimhae 50834, Gyeongnam, Republic of Korea.
- Wasong Agricultural Co., Ltd., Bldg. B, Room 403, 197 Injero, Gimhae 50834, Gyeongnam, Republic of Korea.
- College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, 197 Injero, Gimhae 50834, Gyeongnam, Republic of Korea.
ORCID-Profile: Ji Yeon Hyun, Kyoung Ah Min, Meong Cheol Shin
Förderung
- Ministry of Science and ICT
- Ministry of Education
- Ministry of Food and Drug Safety
- Ministry of Agriculture, Food and Rural Affairs
- National Research Foundation of Korea
- Ministry of SMEs and Startups
Zitieren
APA
Amatya, R., Hyun, J. Y., Lee, J. H., Min, K. A., & Shin, M. C. (2026). AMPK-Directed Therapeutics for MASLD: Mechanistic Rationale, Activator Classes, and Clinical Translation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188358
Vancouver
Amatya R, Hyun JY, Lee JH, Min KA, Shin MC. AMPK-Directed Therapeutics for MASLD: Mechanistic Rationale, Activator Classes, and Clinical Translation. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188358
BibTeX
@article{Amatya2026,
author = {Amatya, Reeju and Hyun, Ji Yeon and Lee, Jun Hak and Min, Kyoung Ah and Shin, Meong Cheol},
title = {AMPK-Directed Therapeutics for MASLD: Mechanistic Rationale, Activator Classes, and Clinical Translation},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188358}
}
EUVIMED